Biased Ligands. Better Drugs.

TRV027 - AT1R Biased Ligand for Acute Heart Failure

ProductTargetIndicationLead OpPreclinPhase 1Phase 2Phase 3
TRV027Angiotensin II
type 1 receptor
Acute Heart Failureintravenous
TRV130Mu-opioid
receptor
Postoperative Painintravenous
TRV734Mu-opioid
receptor
Moderate to Severe Painoral
Delta OpioidDelta-opioid
receptor
Parkinson's, Migraine, Neuropathic Pain 
Collaboration with Actavis

TRV027 is an intravenous drug for the treatment of acute heart failure (AHF) in combination with standard diuretic therapy, and is currently being investigated in a Phase 2 clinical trial. TRV027 is a β-arrestin biased ligand of the angiotensin II type 1 receptor (AT1R). Forest Laboratories Inc. (NYSE:FRX) has an exclusive option to license TRV027.

View TRV027 Publications

Recent TRV027 News

Related Events

  • AHA Scientific Sessions, Chicago, Illinois11/15/2014 - 11/19/2014

    Dr. David Soergel, SVP Clinical Development and Ms. Kathy Goin, VP, Clinical Operations, will be attending the AHA Scientific Sessions in Chicago, Illinois. The event will take place between November 15 - 19 at the McCormick Place convention center.

Copyright © Trevena, Inc.